Those who received Covaxin vaccine will have to wait more for taking up international travel. The emergency use authorisation (EUA) for Covaxin, the Covid vaccine developed in India, has been further delayed as the World Health Organization (WHO) has sent more technical queries to its Hyderabad vaccine manufacturer Bharat Biotech, sources have said.
This comes even after the Hyderabad vaccine manufacturer has been repeatedly saying that it has submitted all data required for clearance of Covaxin.
“It’s the usual process. Experts raise queries, which need to be answered by the company,” the sources said. Without the WHO nod, Covaxin will not be
considered an accepted vaccine by most countries across the world and the delay is likely to affect students, medical tourists, business travellers and those who want to travel abroad.
This delay is likely to adversely affect Indians’, especially students’, international travel plans.